Idexx Laboratories (IDXX) Receivables (2009 - 2026)

Idexx Laboratories' Receivables history runs 18 years deep, the most recent figure standing at $681.2 million for Q1 2026.

• In Q1 2026, Receivables rose 15.39% year-over-year to $681.2 million; the TTM figure through Mar 2026 stood at $681.2 million (up 15.39% YoY), while the FY2025 annual figure was $628.2 million, up 17.57% from the prior year.
• Receivables for Q1 2026 stood at $681.2 million, up from $388.5 million in the prior quarter.
• The five-year high for Receivables was $681.2 million in Q1 2026, with the low at $232.7 million in Q4 2022.
• The 5-year median for Receivables is $512.6 million (2023), against an average of $516.0 million.
• The sharpest annual moves came in 2022 and 2023: Receivables slumped 42.71% in 2022, then surged 120.31% in 2023.
• Idexx Laboratories' Receivables stood at $232.7 million in 2022, then surged by 120.31% to $512.6 million in 2023, then increased by 4.25% to $534.3 million in 2024, then fell by 27.29% to $388.5 million in 2025, then jumped by 75.34% to $681.2 million in 2026.
• Business Quant data shows IDXX's Receivables at $681.2 million in Q1 2026, $388.5 million in Q4 2025, and $638.8 million in Q3 2025.